<DOC>
	<DOCNO>NCT02741544</DOCNO>
	<brief_summary>To understand safety efficacy Revlimid® 2.5mg 5 mg Capsules ( hereinafter refer Revlimid ) patient treat actual condition use pursuant condition approval . 1 . Planned registration period This period start date initial marketing Revlimid end time plan number patient enrol reach . 2 . Planned surveillance period This period start date initial marketing Revlimid end day approval condition relate all-case surveillance terminate .</brief_summary>
	<brief_title>Revlimid® Capsules Special Drug Use-results Survey ( Patients With Newly-diagnosed Multiple Myeloma NDMM )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Newlydiagnosed multiple myeloma treat Revlimid Capsules</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Second primary cancer</keyword>
	<keyword>Cataracts</keyword>
	<keyword>Newly-diagnosed multiple myeloma</keyword>
	<keyword>Revlimid capsule</keyword>
</DOC>